[Clinical use of a GnRH analogue in a depot preparation (leuprolide acetate) in patients with surgical indication for uterine fibromyoma].
During 1992 and 1993, twenty-eight women with uterine leiomyomata received GnRH-agonist (leuprolide acetate) for 3 months before hysterectomy or myomectomy. The decrease in uterine volume and secondary anemia with its collateral effects were assessed, then surgical and post-surgical advantages were assessed too. The real advantages of this treatment are studied and distinguished from theoretic advantages.